Celltrion Will Present Infliximab Clinical Data in October
The company will highlight subcutaneous treatment results for IBD patients at the upcoming UEG Week 2026 symposium.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient access when developing new treatment formulations?
On October 18, 2026, Celltrion will present clinical evidence regarding its Remsima subcutaneous infliximab formulation at UEG Week 2026. This presentation follows the 2026 European launch of the company's liquid Remsima IV formulation.
Why it matters
Celltrion is working to expand its portfolio of inflammatory bowel disease (IBD) treatments as it seeks to strengthen its position in the global market. The symposium will provide a venue to share clinical data on the company's subcutaneous administration approach.
Regulatory bodies in 60 countries have authorized the 120mg fixed dose of CT-P13 SC. This subcutaneous formulation offers an alternative administration route compared to the traditional intravenous liquid formulation.
The players
Celltrion
A South Korean biopharmaceutical company focused on the development and manufacturing of biosimilar and innovative monoclonal antibodies.
Peter M. Irving
A professor serving as chair for the Celltrion symposium.
Irina Blumenstein
A professor presenting clinical data on Remsima SC monotherapy.
The details
CT-P13 SC is a subcutaneous formulation — an injection administered under the skin — of the monoclonal antibody infliximab. Infliximab works by neutralizing tumor necrosis factor-alpha, a protein that triggers inflammation in patients with autoimmune conditions. Clinical evidence being presented explores the use of this formulation as a monotherapy for IBD.
Timeline
October 18, 2026: Celltrion hosts a symposium on subcutaneous infliximab.
The Tech Race
The symposium aligns with broader industry efforts to shift delivery models for monoclonal antibodies from traditional clinic-based infusions to patient-administered subcutaneous injections. This move puts Celltrion in direct competition with established biologics providers in the global IBD market.
Patients with IBD gain access to a 120mg fixed-dose subcutaneous option, which reduces the necessity for clinic-based infusion appointments. Availability remains subject to local healthcare provider prescription and regional regulatory approval status.
The takeaway
Celltrion's continued expansion of subcutaneous infliximab highlights an industry-wide transition toward patient-centric dosing. Clinicians and patients should watch for the data presented on October 18, 2026, to assess the monotherapy efficacy profile of the 120mg dose.
Further reading
For broader trends in drug delivery and biosimilar innovation, see Biotech.
Live Poll
Do you trust that pharmaceutical companies prioritize patient access when developing new treatment formulations?
